(TECX) Tectonic Therapeutic - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 528m USD | Total Return: 31.2% in 12m
Avg Turnover: 6.26M
Warnings
Interest Coverage Ratio -1824.3 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Choppy
Tailwinds
No distinct edge detected
Tectonic Therapeutic, Inc. (TECX) is a clinical-stage biotechnology company specializing in the discovery and development of biologic medicines targeting G protein-coupled receptors (GPCRs). The company utilizes its proprietary GEODe technology platform to engineer therapeutic proteins and antibodies designed to overcome historical challenges in GPCR drug discovery. Its lead candidate, TX45, is a fusion molecule targeting the RXFP1 receptor for cardiovascular and pulmonary applications, while its pipeline includes TX2100 for hereditary hemorrhagic telangiectasia and additional programs focused on fibrosis.
The biotechnology sector frequently targets GPCRs because they represent the largest class of membrane proteins and are involved in a wide range of physiological processes. While approximately one-third of FDA-approved drugs target GPCRs, most are small molecules; Tectonic’s business model focuses on the underserved biologics segment of this market to improve specificity and reduce off-target effects. For a more comprehensive look at these metrics, consider reviewing the detailed data available on ValueRay.
- TX45 clinical trial data readouts drive investor confidence in heart failure pipeline
- GEODe platform success determines scalability of GPCR-targeted biologic drug discovery
- Regulatory approval timelines for TX2100 impact long-term orphan drug market positioning
- R&D expenditure and cash burn rates dictate future equity financing requirements
- Strategic partnerships for bispecific GPCR modulators validate platform commercial potential
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.27 > 0.02 and ΔFCF/TA -6.60 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.27 > 3% & CFO -65.4m > Net Income -83.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 18.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (18.8m) vs 12m ago 9.39% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -1.82k > 6 (EBITDA TTM -91.7m / Interest Expense TTM 51.0k) |
| A: 0.92 (Total Current Assets 239.9m - Total Current Liabilities 13.0m) / Total Assets 246.6m |
| B: -1.01 (Retained Earnings -248.0m / Total Assets 246.6m) |
| C: -0.33 (EBIT TTM -93.0m / Avg Total Assets 280.7m) |
| D: -15.35 (Book Value of Equity -248.0m / Total Liabilities 16.2m) |
| Altman-Z'' = -15.58 = D |
As of May 24, 2026, the stock is trading at USD 28.52 with a total of 96,983 shares traded.
Over the past week, the price has changed by +4.41%,
over one month by +2.18%,
over three months by +37.42% and
over the past year by +31.17%.
Tectonic Therapeutic has received a consensus analysts rating of 4.83. Therefore, it is recommended to buy TECX.
- StrongBuy: 5
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 77.9 | 173.1% |
Revenue TTM = 0.0 USD
EBIT TTM = -93.0m USD
EBITDA TTM = -91.7m USD
Long Term Debt = 3.20m USD (estimated: total debt 4.63m - short term 1.43m)
Short Term Debt = 1.43m USD (from shortTermDebt, last quarter)
Debt = 4.63m USD (from shortLongTermDebtTotal, last quarter) (leases 4.63m already included)
Net Debt = -232.3m USD (calculated: Debt 4.63m - CCE 236.9m)
Enterprise Value = 296.1m USD (528.3m + Debt 4.63m - CCE 236.9m)
Interest Coverage Ratio = -1.82k (Ebit TTM -93.0m / Interest Expense TTM 51.0k)
EV/FCF = -4.51x (Enterprise Value 296.1m / FCF TTM -65.7m)
FCF Yield = -22.18% (FCF TTM -65.7m / Enterprise Value 296.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 1.20 (Enterprise Value 296.1m / Total Assets 246.6m)
Interest Expense / Debt = 1.10% (Interest Expense 51.0k / Debt 4.63m)
Taxrate = 21.0% (US default 21%)
NOPAT = -73.5m (EBIT -93.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 18.51 (Total Current Assets 239.9m / Total Current Liabilities 13.0m)
Debt / Equity = 0.02 (Debt 4.63m / totalStockholderEquity, last quarter 230.4m)
Debt / EBITDA = 2.53 (negative EBITDA) (Net Debt -232.3m / EBITDA -91.7m)
Debt / FCF = 3.54 (negative FCF - burning cash) (Net Debt -232.3m / FCF TTM -65.7m)
Total Stockholder Equity = 258.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -29.74% (Net Income -83.5m / Total Assets 246.6m)
RoE = -16.49% (Net Income TTM -83.5m / Total Stockholder Equity 506.2m)
RoCE = -18.26% (EBIT -93.0m / Capital Employed (Equity 506.2m + L.T.Debt 3.20m))
RoIC = -31.27% (negative operating profit) (NOPAT -73.5m / Invested Capital 235.1m)
WACC = 11.92% (E(528.3m)/V(533.0m) * Re(12.02%) + D(4.63m)/V(533.0m) * Rd(1.10%) * (1-Tc(0.21)))
Discount Rate = 12.02% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 105.3%
[DCF] Fair Price = unknown (Cash Flow -65.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.15 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.35 | Chg30d=-12.92% | Revisions=-64% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-1.37 | Chg30d=-9.72% | Revisions=-50% | Analysts=8
EPS current Year (2026-12-31): EPS=-5.32 | Chg30d=-8.99% | Revisions=-38% | GrowthEPS=-31.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-5.63 | Chg30d=-4.13% | Revisions=-38% | GrowthEPS=-5.7% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -64%